Hemolyzed Samples Should be Processed for Coagulation Studies: The Study of Hemolysis Effects on Coagulation
S Arora1, S Kolte1, Js Dhupia1
1Department of Pathology, VMMC and Safdarjang Hospital, New Delhi, India.
Annals of Medical and Health Sciences Research
|April 25, 2014
Summary
Hemolysis in blood samples minimally impacts coagulation tests like prothrombin time (PT) and activated partial thromboplastin time (aPTT). Visible hemolysis does not necessitate rejecting samples for routine coagulation screening.
Area of Science:
- Clinical Pathology
- Hematology
Background:
- Clinical and Laboratory Standards Institute guidelines advise rejecting hemolyzed specimens for coagulation studies.
- Hemolyzed specimens are frequently encountered in clinical laboratories.
- The clinical impact of hemolysis on coagulation testing remains understudied.
Purpose of the Study:
- To investigate alterations in prothrombin time (PT) and activated partial thromboplastin time (aPTT) in hemolyzed blood samples.
- To assess the clinical significance of hemolysis in routine coagulation testing.
Main Methods:
- Collected 45 blood samples from healthy donors and patients.
- Performed PT and aPTT on fresh samples, then induced hemolysis and re-tested.
- Utilized GraphPad Prism 5 for statistical analysis with a paired t-test (significance level 0.05).
Main Results:
- Observed a trend of increased PT and aPTT readings in the healthy donor group.
- Noted a trend of decreased PT and aPTT readings in the patient group.
- Found statistically insignificant differences in the healthy group but significant differences in the patient group.
Conclusions:
- Visible hemolysis in samples for routine coagulation screening does not preclude processing.
- No significant difference was observed between hemolyzed and non-hemolyzed samples in this study.
- Rejection of all hemolyzed samples for coagulation studies may not be necessary.
More Related Videos
08:44An In Vitro Hemodynamic Loop Model to Investigate the Hemocytocompatibility and Host Cell Activation of Vascular Medical Devices
Published on: August 21, 2020
8.0K
10:25Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
Published on: March 19, 2016
9.1K
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:05Introduction to Hemostasis
14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
01:09Coagulation
8.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.4K